UTHR

UTHR

United Therapeutics

$563.49

+1.74% Oct 21 close

Health CareS&P 400 Compare

1M 3M 6M 1Y 2Y

UTHRSPY

+4.3%

+14.3%

+6.9%

-1.9%

YTD

+15.6%

+33.4%

Live chart

Loading live chart…

What they do

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer. It also markets and sells Unituxin (dinutuximab) injection.

Healthcare · Drug Manufacturers - Specialty & Generic

For information only · Important disclosures

Grades vs sector

Momentum

53rd percentile in sector

C+

12-1 return: +21.7%
Percentile within its GICS sector across the S&P 1500.

Growth

8th percentile in sector

Revenue growth (YoY): -1.9%
Percentile within its GICS sector across the S&P 1500.

Value

63rd percentile in sector

B-

Forward E/P: 6.3% · EBITDA/EV: 7.4%
Percentile within its GICS sector across the S&P 1500.

Profitability

84th percentile in sector

A-

Profit margin: +41.6% · Return on equity: +19.3%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

ranked 64 of 589 · 12-month momentum 20.3%

Coteau Long Book

Not in the current book

News

More news

No recent headlines.

Key stats

52-week range$415.34 – $596.76

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Looks undervalued

Model read-out from the numbers below, not advice. Score +3 (DCF counts double).

▲DCF (base case)above the price by 72%

▲Piotroski F-score8/9

▲Net debt / EBITDA-1.8x

Discounted cash flow

Bear

$569

+1%

growth 11% · disc. 10.2% · term. 2.0%

Base

$972

+72%

growth 18% · disc. 9.2% · term. 2.5%

Bull

$1,558

+177%

growth 23% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

86.1%

Operating margin

44.4%

FCF margin

34.6%

Net margin

41.6%

Return on equity

20.5%

Return on invested capital

31.3%

Net debt / EBITDA

-1.8×

Current ratio

5.7×

Interest cover

116.8×

Cash conversion (OCF/NI)

1.3×

Piotroski F-score 8/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$3.2B	$1.3B	$1.0B
2024	$2.9B	$1.2B	$1.1B
2023	$2.3B	$984.8M	$747.6M
2022	$1.9B	$727.3M	$663.7M
2021	$1.7B	$475.8M	$477.4M
2020	$1.5B	–	$696.4M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +18.0%.

Earnings

Next report: 2026-11-04 · before open · EPS est 6.06

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-05	6.86	7.27	+6.0%
2026-05-06	6.86	5.82	-15.1%
2026-02-25	6.76	7.70	+14.0%
2025-10-29	6.96	7.16	+2.9%
2025-07-30	7.30	6.41	-12.2%
2025-04-30	6.54	6.63	+1.3%
2025-02-26	6.84	6.19	-9.5%
2024-10-30	7.12	7.07	-0.7%

Insider trades

Rothblatt Martine A